Suppr超能文献

探索表面活性剂在更高载药量下增强无定形固体分散体药物释放中的作用。

Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings.

作者信息

Saboo Sugandha, Bapat Pradnya, Moseson Dana E, Kestur Umesh S, Taylor Lynne S

机构信息

Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.

Oral Formulation Sciences and Technology, Merck & Co., Inc., Rahway, NJ 07065, USA.

出版信息

Pharmaceutics. 2021 May 17;13(5):735. doi: 10.3390/pharmaceutics13050735.

Abstract

To reduce the dosage size of amorphous solid dispersion (ASD)-based formulations, it is of interest to devise formulation strategies that allow increased drug loading (DL) without compromising dissolution performance. The aim of this study was to explore how surfactant addition impacts drug release as a function of drug loading from a ternary ASD, using felodipine as a model poorly soluble compound. The addition of 5% TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate, a surfactant) to felodipine-polyvinylpyrrolidone/vinyl acetate ASDs was found to facilitate rapid and congruent (i.e., simultaneous) release of drug and polymer at higher DLs relative to binary ASDs (drug and polymer only). For binary ASDs, good release was observed for DLs up to <20% DL; this increased to 35% DL with surfactant. Microstructure evolution in ASD films following exposure to 100% relative humidity was studied using atomic force microscopy coupled with nanoscale infrared imaging. The formation of discrete, spherical drug-rich domains in the presence of surfactant appeared to be linked to systems showing congruent and rapid release of drug and polymer. In contrast, a contiguous drug-rich phase was formed for systems without surfactant at higher DLs. This study supports the addition of surfactant to ASD formulations as a strategy to increase DL without compromising release. Furthermore, insights into the potential role of surfactant in altering ASD release mechanisms are provided.

摘要

为了减小基于无定形固体分散体(ASD)制剂的剂量大小,设计出在不影响溶出性能的情况下提高药物载量(DL)的制剂策略很有意义。本研究的目的是探讨添加表面活性剂如何影响作为三元ASD药物载量函数的药物释放,使用非洛地平作为难溶性化合物模型。相对于二元ASD(仅药物和聚合物),发现向非洛地平 - 聚乙烯吡咯烷酮/醋酸乙烯酯ASD中添加5%的TPGS(d-α-生育酚聚乙二醇1000琥珀酸酯,一种表面活性剂)可促进在较高药物载量下药物和聚合物的快速且一致(即同时)释放。对于二元ASD,在药物载量高达<20%时观察到良好的释放;添加表面活性剂后,这一载量增加到35%。使用原子力显微镜结合纳米级红外成像研究了ASD薄膜在暴露于100%相对湿度后的微观结构演变。在表面活性剂存在下形成离散的、富含药物的球形区域似乎与显示药物和聚合物一致且快速释放的体系有关。相比之下,在较高药物载量下,没有表面活性剂的体系形成了连续的富含药物相。本研究支持在ASD制剂中添加表面活性剂作为在不影响释放的情况下增加药物载量的策略。此外,还提供了关于表面活性剂在改变ASD释放机制中潜在作用的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0b/8156319/5a2ea2a860dc/pharmaceutics-13-00735-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验